Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

FDA Approves Tocilizumab Biosimilar for CAR T-Cell Therapy–Induced CRS

August 6th 2025

The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.

FDA Grants Priority Review to Liso-Cel for R/R Marginal Zone Lymphoma

August 4th 2025

The FDA granted priority review to a supplemental biologics license application for lisocabtagene maraleucel in relapsed/refractory marginal zone lymphoma.

Voices in Lymphoma: Women Shaping the Future of Care

August 4th 2025

Clémentine Sarkozy, MD, PhD, and Carla Casulo, MD, detail the evolution of lymphoma management strategies.

OncLive’s July Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

August 1st 2025

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.

The OncFive: Top Oncology Articles for the Week of 7/20

July 26th 2025

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

CTCL Today: Remaining Unmet Needs in CTCL

July 25th 2025

Panelists discuss how unmet needs in cutaneous T-cell lymphoma include the lack of a cure, the need for better biomarkers for early diagnosis and treatment response prediction; improving patients' quality of life by managing symptoms, such as itch; advancing understanding of disease biology to develop effective targeted therapies, such as cell therapy; and the importance of multidisciplinary care and clinical trial participation.

The OncFive: Top Oncology Articles for the Week of 7/13

July 19th 2025

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.

FDA Issues CRL for Glofitamab Plus Chemo in R/R DLBCL

July 18th 2025

The FDA issued a CRL to the application for glofitamab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.

When to Consider Allogeneic Transplant in CTCL, and Clinical Pearls for Community Providers

July 18th 2025

Panelists discuss how stem cell transplantation is considered primarily for younger patients or aggressive CTCL variants, balancing timing, remission status, and potential risks, while also emphasizing the value of early referral and specialized guidance for advanced disease.

Clinical Perspectives: When to Revisit a Prior Therapies in Mycosis Fungoides and Sézary Syndrome

July 18th 2025

Panelists discuss how decisions about reintroducing previous therapies for CTCL are based on prior tolerance, current disease state, and the reason for stopping treatment, with flexibility to recycle effective agents when appropriate.

ELM-2 Data Display Long-Term Efficacy and Safety of Odronextamab in R/R Follicular Lymphoma

July 15th 2025

Stefano Luminari, MD, discusses unmet needs for patients with follicular lymphoma, updated data from the ELM-2 trial, and infection risk management advice.

Monitoring Mogamulizuma: Managing and Differentiating Drug vs. Disease-Related Rash

July 11th 2025

Panelists discuss how to differentiate Mogamulizumab-associated rash from CTCL using clinical clues, biopsy findings, and molecular studies, and how treatment may be modified based on rash severity and characteristics.

Personalizing Care: Treatment Decisions in Sézary Syndrome

July 11th 2025

Panelists discuss how to sequence and personalize therapy for Sézary syndrome, with mogamulizumab often used as first-line treatment due to potential for durable remission, followed by HDAC inhibitors, photopheresis, or alemtuzumab depending on disease progression and transplant planning.

The OncFive: Top Oncology Articles for the Week of 6/29

July 5th 2025

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.

Expert Perspectives: Combination Therapies in Advanced-Stage MF

July 2nd 2025

Panelists discuss how to integrate skin-directed therapies with systemic treatments for CTCL, emphasizing individualized strategies based on disease compartment, cautious layering of treatments, management of bacterial colonization (especially Staphylococcus aureus), and use of adjunctive measures, such as bleach baths, for optimizing skin health.

Treatment Challenges in Advanced Mycosis Fungoides: High Blood Burden or Nodal Disease

July 2nd 2025

Panelists discuss how to manage advanced-stage mycosis fungoides with nodal or visceral involvement by adapting treatments typically used for peripheral T-cell lymphoma, including single-agent chemotherapy and HDAC inhibitors, while accounting for long-term toxicities and unique dose considerations due to patient fragility and tumor biology.

OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025

July 1st 2025

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

FDA Removes REMS Programs for All Currently Approved CD19- and BCMA-Directed CAR T-Cell Therapies in Hematologic Malignancies

June 30th 2025

The FDA has eliminated REMS programs for BCMA- and CD19-directed autologous CAR T-cell therapies approved for multiple myeloma and select types of lymphoma/leukemia.

FDA Approves Changes to Monitoring Requirements, Removal of REMS Programs for Liso-Cel and Ide-Cel in B-Cell Malignancies

June 27th 2025

The FDA updated the labels for liso-cel and ide-cel to reduce monitoring select requirements and remove REMS programs for the CAR T-cell therapies.

Future of DLBCL Therapy Hinges on Optimal Use of CAR T-Cell Therapy, Bispecifics, and Other Novel Strategies

June 26th 2025

Alexey Danilov, MD, PhD, highlights the importance of re-evaluating sequencing strategies amid a growing arsenal of targeted therapies in DLBCL.